Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Author affiliation: Mayo Clinic, Rochester, Minnesota, USA (M. Shieb, J.K. Heimbach, S.H. Ibrahim, B. Pritt, B. Schiltz, E.H. Ristagno); Stanford University, Stanford, California, USA (S. Grama Srinivasan); Minnesota Department of Health, St. Paul, Minnesota, USA (E. Schiffman, A. Garvin); Indiana Department of Health, Indianapolis, Indiana, USA (J. Brown, K.L. Richardson); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D.W. McCormick, S.E. Karpathy, A.N. Gleaton, C. Ramos, J. Singleton, P. Annambhotla, S.V. Basavaraju, J. Kasten, C.D. Paddock, J.S. Salzer)
Ehrlichiosis is characterized by influenza-like symptoms such as fever, headache, nausea, and muscle aches. In the United States, ehrlichiosis can be caused by infections from 3 pathogenic tickborne bacterial species, Ehrlichia chaffeensis, Ehrlichia ewingii, and Ehrlichia muris subsp. eauclairensis. The epidemiology of E. chaffeensis and E. ewingii is associated with the distribution of the lone star tick (Amblyomma americanum), which occurs primarily in the northeastern, southern, and midwestern United States. E. muris subsp. eauclairensis infections are isolated to Wisconsin and Minnesota and transmitted by the blacklegged tick (Ixodes scapularis) (1).
During 2008–2022, a total of 327 cases of E. ewingii infection from 28 states were reported to the Centers for Disease Control and Prevention (CDC), compared with 19,918 cases of E. chaffeensis infections from 47 states (2,3). E. ewingii infections are likely underreported because diagnosis relies on serologic assays that cannot differentiate among Ehrlichia species. The nonspecific clinical signs and symptoms of ehrlichiosis and gaps in healthcare provider knowledge contribute to underdiagnosis and underreporting (2). Ehrlichiosis is uncommon among transplant recipients, and donor-derived infections are exceedingly rare (4). Here, we report on a case of E. ewingii infection in a pediatric liver recipient.
In the fall of 2023, a child 10–15 years of age with end-stage liver disease secondary to primary sclerosing cholangitis underwent deceased donor liver transplantation. The child had no travel outside the state in which the transplant was performed within the 10 weeks before the surgery and had no outdoor or animal exposures and no known tick bites. The child permanently resided outside the United States, in an area where ehrlichiosis has not been reported.
Transplant surgery was uncomplicated and required only autologous cell saver transfusion. At transplantation, serologic testing revealed IgG to Epstein-Barr virus and cytomegalovirus in both the donor and recipient. The liver recipient received intravenous (IV) methylprednisolone (500 mg, followed by 50 mg every 12 h with taper), mycophenolate mofetil (883 mg IV every 12 h, transitioned to 1,000 mg oral every 12 h), and oral tacrolimus (3 mg every 12 h), as part of standard immunosuppressive therapy. Ten days after transplantation, a biopsy revealed mild acute cellular rejection in the patient. The patient was treated with IV methylprednisolone (1,000 mg every other day for 3 doses). Asymptomatic cytomegalovirus viremia developed in the patient 12 days after transplantation and resolved with oral valganciclovir (900 mg every 12 h).
The patient reported fever, headache, dyspnea, and severe nausea 18 days after transplantation and was admitted to the hospital. Blood and urine cultures yielded no growth, and imaging revealed no abnormalities; laboratory testing showed anemia, leukopenia, and thrombocytopenia. During the next 72 hours, progressive tachypnea developed in the patient, oxygen saturation decreased, and fever persisted (maximum temperature 40.5°C). The patient was started on intravenous doxycycline (100 mg 2×/d) 24 days after transplantation for suspected atypical pneumonia and tickborne disease infection. Within 24 hours of treatment, the patient’s fever resolved, other symptoms improved, and laboratory abnormalities resolved.
At initiation of doxycycline treatment, examination of a peripheral smear revealed findings in granulocytes suggestive of Anaplasma or Ehrlichia species bacteria (Figure). Mayo Clinic (Rochester, MN, USA) performed real-time PCR for E. ewingii and Ehrlichia canis on a whole-blood sample collected 24 days after transplantation; results were positive (5). CDC (Atlanta, GA, USA) performed confirmatory testing by using real-time PCRs targeting segments of the 16S rRNA gene. Testing detected Ehrlichia spp. DNA but not E. chaffeensis DNA. Subsequent partial 16S rRNA sequencing confirmed the presence of E. ewingii DNA.
The patient continued doxycycline treatment, and clinicians changed Pneumocystis jirovecii prophylaxis from oral trimethoprim/sulfamethoxazole (160/800 mg 3×/wk) to inhaled pentamidine (300 mg) because of a potential contraindication to trimethoprim/sulfamethoxazole in rickettsial infections (6). Because ehrlichiosis is nationally notifiable in the United States, clinicians reported the case to public health officials.
The Department of Health in the state where the transplant surgery occurred initiated an epidemiologic investigation, in collaboration with CDC and the Department of Health in the state where the deceased donor resided. The deceased donor resided in an area where E. ewingii has been identified in A. americanum ticks and human cases have been reported (2). Thirty days before organ donation, the donor sought medical care for a mild, self-limiting illness compatible with ehrlichiosis, including headache, abdominal pain, nausea, and chills. The donor subsequently died of a confirmed noninfectious cause.
CDC retrospectively tested serum collected from the donor at organ procurement by using an indirect immunofluorescence antibody assay, which detected IgG reactive with E. chaffeensis at a titer of 1:2,048. CDC testing did not detect Ehrlichia spp. DNA by using real-time PCR in donor serum or in a whole-blood sample collected from the recipient on the day of transplantation (7). CDC tested liver allograft biopsy specimens obtained before and after transplantation and did not detect Ehrlichia spp. antigens by using immunohistochemistry or Ehrlichia spp. DNA by using real-time PCR (8). The clinical history and geographic location of the donor, along with laboratory evidence, strongly supports a donor-derived E. ewingii infection.
Surgeons also transplanted both donor kidneys. Investigators notified the treating clinicians for both kidney recipients of possible transplant-associated infection. Neither kidney recipient reported signs or symptoms associated with ehrlichiosis. PCR testing of whole-blood samples from the recipients did not detect Ehrlichia spp. DNA, and serologic testing was not performed.
The liver recipient was discharged on day 28 after transplantation with oral doxycycline (100 mg 2×/d). Mayo Clinic performed additional real-time PCR testing (5) for E. ewingii and E. canis on whole-blood samples collected from the liver recipient on days 35, 42, 49, and 56 after transplantation (days 11, 19, 25, and 32 of doxycycline treatment); all samples yielded positive results (Table). On day 67 after transplantation (day 43 of doxycycline treatment), real-time PCR testing for E. ewingii and E. canis on a whole-blood sample from the liver recipient yielded negative results (Table). Subsequent real-time PCR testing on day 68 after transplantation yielded negative results, and clinicians discontinued doxycycline treatment. However, on day 98 after transplantation, real-time PCR testing of a whole-blood sample yielded positive results. At that time, the patient had a cough, and chest radiography revealed peribronchial thickening not attributable to ehrlichiosis. Clinicians subsequently treated the patient with albuterol and systemic steroids and reinitiated doxycycline treatment. Real-time PCR testing for E. ewingii and E. canis PCR revealed alternating negative and positive results in the subsequent days, suggesting low-level bacteremia (Table). Of note, the patient remained asymptomatic, and serologic testing did not detect antibodies reactive to E. chaffeensis throughout the follow-up period. The patient remained on doxycycline for an extended period of >273 days after transplantation. The patient did not return for the requested infectious diseases follow-up, and subsequent attempts to contact the family after day 273 were unsuccessful.
Our report summarizes an investigation into a pediatric liver recipient with an E. ewingii infection. The recipient’s lack of recognized tick exposure, combined with the donor’s clinical history, residence in an area where E. ewingii has been identified, and laboratory findings, strongly supports transmission through the liver allograft. Persistent and intermittently detectable E. ewingii DNA despite prolonged doxycycline treatment highlights challenges in managing ehrlichiosis in immunosuppressed transplant recipients.
Early initiation of doxycycline treatment in patients of all ages with suspected ehrlichiosis, without waiting for laboratory confirmation, is crucial to reduce the risk for severe outcomes (1). For immunocompetent persons with suspected ehrlichiosis, doxycycline treatment should continue for >3 days postdefervescence and until clinical improvement is evident, typically for a total of 5–7 days (9). The liver recipient in this report was immunosuppressed and continued doxycycline treatment until PCR testing no longer detected Ehrlichia spp. DNA in a blood sample, which occurred after 43 days of treatment. The infection recrudesced 30 days after doxycycline was discontinued. Therefore, we recommend considering periodic surveillance of immunocompromised patients with ehrlichiosis by using quantitative PCR after treatment completion, or continuing treatment until immune function has recovered (9).
The absence of E. ewingii transmission to either kidney recipient could reflect several factors. First, the larger tissue volume and increased vascularity of hepatic allografts relative to kidney allografts might result in a larger inoculum in the liver recipient (10). Second, phagocytic Kupffer cells in the transplanted liver could have provided an intracellular niche in which ehrlichiae could concentrate and remain viable. Last, induction and maintenance therapy for the liver recipient results in a greater degree of immunosuppression compared to either kidney recipient.
In summary, this case report sheds light on a rare E. ewingii infection after liver transplantation in a pediatric patient, underscoring the importance of a multidisciplinary approach by including infectious disease specialists early, maintaining a broad diagnostic approach considering exposure history of the donor, including consideration of vector-borne diseases that are not endemic to the recipient’s region, and the value of early reporting. Early reporting and collaboration with public health officials initiates traceback investigations to ensure all clinicians treating other organ recipients associated with a common donor are properly notified and treated appropriately to prevent further disease or death.
Dr. Shieb is a pediatric infectious diseases fellow in the Division of Pediatric Infectious Diseases at Mayo Clinic in Rochester, Minnesota, USA. His research focuses on infections in the immunocompromised host.